Hisashi Mitsufuji

Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non–Small-Cell Lung Cancer: A Prospective Observational Study

Tomoya Fukui, Yuriko Okuma, Yoshiro Nakahara et al. · Clinical Lung Cancer · 2018 · 106 citations

Prognostic Biomarkers, Cancer Immunosurveillance, Lung Inflammation +9

Antiinflammatory Properties of Inducible Nitric Oxide Synthase in Acute Hyperoxic Lung Injury

Hirosuke Kobayashi, Ryuji Hataishi, Hisashi Mitsufuji et al. · American Journal of Respiratory Cell and Molecular Biology · 2001 · 68 citations

Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer

Masayuki Shirasawa, Tomoya Fukui, Seiichiro Kusuhara et al. · PLoS ONE · 2019 · 39 citations · Full text

Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease

Tomoya Fukui, Sakiko Otani, Ryuji Hataishi et al. · Cancer Chemotherapy and Pharmacology · 2009 · 34 citations

Oncology, Egfr-mutant Lung Adenocarcinoma, Pathology +7

Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer

Masayuki Shirasawa, Tomoya Fukui, Seiichiro Kusuhara et al. · Cancer Management and Research · 2018 · 28 citations · Full text